NCT06906341 · Corcept Therapeutics
Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
What this study is about
This is a Phase 2, single-treatment group$1, where both patients and doctors know the treatment given study to evaluate effectiveness and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.
View original scientific description
This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.
Interventions
DRUG
Relacorilant 150 mg once daily (QD)
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
DRUG
Nab-paclitaxel 80 mg/m^2
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
DRUG
Bevacizumab 10 mg/kg
Bevacizumab is administered as IV infusion on Days 1 and 15.
Primary outcome measures
Progression-Free Survival (PFS)
Time frame: Date of first dose until PD or death, up to 18 months
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Histologic diagnosis of high-grade serous/endometrioid, epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma.
- Platinum-resistant disease (defined as progression \<183 days from the last dose of platinum).
- At least 1 measurable (target) lesion per RECIST version 1.1.
- Life expectancy of ≥3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Able to swallow and retain oral medication and does not have uncontrolled emesis.
- 1 to 3 lines of prior systemic anticancer therapy for ovarian cancer. 1. ≥1 prior line of platinum-based therapy. 2. Prior treatment with bevacizumab allowed.
- Adequate organ function meeting the following laboratory-test criteria: 1. Absolute neutrophil count (ANC) ≥1500 cells/mm\^3. 2. Platelet count ≥100,000/mm\^3. 3. Hemoglobin ≥9 g/dL. 4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN if liver metastases. 5.
Where
- Birmingham, Alabama
- Palo Alto, California
- San Francisco, California
- Fort Myers, Florida
- Miami Beach, Florida
- West Palm Beach, Florida
- Minneapolis, Minnesota
- Kansas City, Missouri
- St Louis, Missouri
- Albuquerque, New Mexico
- Centerville, Ohio
- Eugene, Oregon
And 4 more locations — see the full list below.
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Apr 14, 2026 · Source of record for eligibility and locations